Financial Data and Key Metrics Changes - Q3 subscription revenue grew 19% to $286 million, representing 96% of total revenue [24][4] - Confluent Cloud revenue increased 24% to $161 million, accounting for 56% of subscription revenue compared to 54% in the previous year [24][4] - Non-GAAP operating margin expanded three percentage points to approximately 10% [4] - Subscription gross margin was 81.8%, above the long-term target of 80% [26] - Operating margin increased 340 basis points to a record 9.7%, exceeding guidance by 270 basis points [26] - Adjusted free cash flow margin increased 450 basis points to 8.2% [26] Business Line Data and Key Metrics Changes - Confluent Platform revenue grew 14% to $125.4 million, driven by demand in financial services [24] - Flink ARR for Confluent Cloud grew more than 70% sequentially, with over 1,000 customers using Flink [31][7] - The number of customers with $100k+ ARR increased to 2,533, up 36 sequentially [27] - The number of customers with $1 million+ ARR increased to 234, representing a growth acceleration of 27% [27] Market Data and Key Metrics Changes - Revenue from the U.S. grew 13% to $172.1 million, while revenue from outside the U.S. grew 29% to $126.4 million [24] - Net retention rate stabilized at 114%, with gross retention rate close to 90% [27] Company Strategy and Development Direction - The company is focused on tightening field alignment to drive more use cases into production and expanding its DSP specialist team for multiproduct selling [6][7] - The partner ecosystem sourced over 25% of new business in the last twelve months, indicating strong growth potential [10][11] - The company aims to position itself as a leader in providing real-time data context for AI applications, emphasizing the importance of data streaming in AI deployment [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong cloud consumption growth and the overall performance of the data streaming platform [22][36] - The company expects subscription revenue for 2025 to be in the range of $295.5 million to $296.5 million, representing approximately 18% growth [29] - For fiscal year 2025, subscription revenue is expected to be between $1.1135 billion and $1.1145 billion, indicating approximately 21% growth [29] Other Important Information - The company highlighted the successful integration and growth of WarpStream, which has seen eightfold growth in consumption since its acquisition [14][35] - The company has maintained a win rate above 90% in replacing CSP streaming offerings, with average deal sizes more than doubling over the past two quarters [11][12] Q&A Session Summary Question: Insights on go-to-market changes and pipeline conversion trends - Management noted that the specialization model for DSP and field execution improvements have driven strong pipeline progression, with high confidence in the late-stage pipeline [40][41] Question: RPO and CRPO as leading indicators - Management confirmed that RPO is a key leading indicator for the Confluent platform, while for Confluent Cloud, the focus is on new use cases moving into production [45][46] Question: Growth outlook and cannibalization effects - Management indicated that new offerings have proven to be a substantial tailwind, leading to larger deal sizes and increased customer engagement [54] Question: Flink adoption and future business impact - Management expressed excitement about Flink's growth and its potential to drive significant business opportunities in the future [76][78] Question: AI use cases and customer readiness - Management highlighted various AI use cases across industries, emphasizing the importance of data flow and quality in achieving successful AI deployments [86][87]

Financial Data and Key Metrics Changes - Q3 subscription revenue grew 19% to $286.3 million, representing 96% of total revenue [19][20] - Confluent Cloud revenue increased 24% to $161 million, accounting for 56% of subscription revenue compared to 54% in the previous year [19][20] - Non-GAAP operating margin expanded 3 percentage points to approximately 10% [3] - Subscription gross margin was 81.8%, exceeding the long-term target of 80% [20] - Operating margin increased 340 basis points to a record of 9.7% [20] - Adjusted free cash flow margin rose 450 basis points to 8.2% [20] Business Line Data and Key Metrics Changes - Confluent Platform revenue grew 14% to $125.4 million, driven by demand in financial services [19] - Flink ARR for Confluent Cloud grew more than 70% sequentially, with over 1,000 customers using Flink [25][26] - The number of $100K+ ARR customers increased to 1,487, marking the largest sequential increase in two years [21] - The $1 million+ ARR customer count rose to 234, representing a 27% growth acceleration [21] Market Data and Key Metrics Changes - Revenue from the U.S. grew 13% to $172.1 million, while revenue from outside the U.S. grew 29% to $126.4 million [20] - RPO (Remaining Performance Obligations) grew 43%, indicating strong future revenue visibility [24] Company Strategy and Development Direction - The company is focusing on tightening field alignment to drive more use cases into production, with over 40% sequential growth in late-stage pipeline [4][24] - There is a strong emphasis on expanding the Data Streaming Platform (DSP) and multi-product selling, particularly with Flink [5][26] - The partner ecosystem is contributing significantly, with over 25% of new business sourced from partners [8][26] - The company aims to position its Data Streaming Platform as the context layer for enterprise AI, facilitating the transition from AI experimentation to production [16][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong cloud consumption growth and the traction of the Data Streaming Platform, particularly with Flink [17][27] - The outlook for Q4 2025 includes expected subscription revenue in the range of $295.5 to $296.5 million, representing approximately 18% growth [22] - For fiscal year 2025, subscription revenue is expected to be between $1.1135 to $1.1145 billion, indicating approximately 21% growth [23] Other Important Information - The company ended Q3 with $1.99 billion in cash, cash equivalents, and marketable securities, reflecting a strong balance sheet [20] - The WarpStream acquisition has seen 8x growth in consumption since its acquisition [11][26] Q&A Session Summary Question: Insights on go-to-market changes and pipeline conversion trends - Management highlighted the effectiveness of the specialization model for DSP and the high confidence in the late-stage pipeline, which is expected to drive future consumption [29][30] Question: RPO and CRPO as leading indicators - RPO is considered a key leading indicator for Confluent Platform, while for Confluent Cloud, the focus is on the momentum of new use cases moving into production [31][32] Question: Growth stabilization and cloud business outlook - Management noted that the cloud business has shown stability, with positive trends in new use cases and product adoption [34] Question: Impact of new offerings on core streaming business - New offerings have proven to be a substantial tailwind, leading to larger deal sizes and increased customer engagement [37] Question: Flink's growth and future potential - Flink has seen significant adoption, with over 1,000 paying customers, and management is optimistic about its future growth potential [56] Question: AI use cases and customer readiness - Management indicated that AI use cases are broad, with many enterprises actively pursuing projects across various sectors [61]

Core Insights - The Fund underperformed the MSCI World ex USA Index for the quarter but has outperformed the benchmark since inception [5] - Consumer discretionary and materials sectors were the largest contributors to performance, while industrials and communication services were the largest detractors [5] - Geographically, the portfolio is heavily weighted towards Europe ex U.K. (68.4%), followed by the U.K. (11.5%) and Asia ex Japan (9.3%) [5] Performance Analysis - Kering was the top contributor during the quarter, driven by leadership changes and improving revenue trends [7] - CNH Industrial was the top detractor, facing weak results and soft demand, particularly in the U.S., but management expects a rebound in 2025 [8] Portfolio Activity - Six new positions were added to the Fund, while nine were exited during the quarter [9] - New purchases included Bunzl, which is expected to return to stable growth despite recent execution issues [10] - Dassault Systèmes, a leader in virtual twin technology, is viewed as a high-quality investment opportunity despite a nearly 40% decline in share price [11] Company Highlights - FEMSA, a diversified Latin American conglomerate, is well-positioned for growth through strategic divestments and share buybacks [12] - Hexagon has upgraded its management team and is expected to see improvements in return on capital employed and cash flow [13] - Siemens Healthineers is positioned for profitable growth in medical technology, with a favorable product cycle and turnaround in its diagnostics business [16] Investment Returns - The Fund's average annualized total returns show strong performance across various time frames, with the Institutional Class returning 26.51% year-to-date [18]

Group 1: Siemens Healthineers Stake - Siemens AG is exploring a separation of its approximately 71% stake in Siemens Healthineers, considering a direct distribution of shares to its shareholders instead of a traditional IPO or spinoff [1] - This approach is unusual in the German market, where large stakes are typically sold gradually or through secondary offerings [2] - The mechanics of the direct distribution under German corporate and tax law will be closely monitored if Siemens proceeds with this plan [2] Group 2: Canada Packers Spin-off - Maple Leaf Foods has completed the separation of its pork operations, resulting in Canada Packers Inc., effective October 1 [3] - This separation allows investors to value Canada Packers independently on public markets [3] - Maple Leaf retains a ~16% stake in Canada Packers and has signed an evergreen supply agreement, remaining an anchor customer [7] Group 3: Aptiv's Strategic Shift - Aptiv is reconsidering its plans to spin off its electrical distribution systems business and may instead pursue an outright sale of the unit [4] - A shift from a spinoff to a sale could provide immediate cash proceeds but may limit long-term upside for investors [5]

Market Overview - European markets closed higher, driven by optimism regarding potential interest rate cuts from the Federal Reserve and positive sentiment surrounding artificial intelligence, despite concerns over a U.S. government shutdown [1] - The pan-European Stoxx 600 index increased by 0.5%, with notable gains in the U.K.'s FTSE 100 (up 0.67%), France's CAC 40 (up 0.31%), and Switzerland's SMI (up 0.64%) [2] Sector Performance - Financial, mining, and energy sectors were among the prominent gainers in the European markets [1] - In the U.K., companies such as Bunzl (up 4.5%), Natwest Group, and others saw gains between 2% to 4%, while Coca-Cola Europacific Partners and others experienced losses of 1% to 2% [3] - German companies like Merck, Rheinmetall, and Siemens Healthineers reported sharp gains, while Siemens Energy and others faced losses [4] Economic Data - The HCOB Germany Composite PMI was revised lower to 52 in September, indicating strong growth in private sector activity compared to 50.5 in August [5] - Eurozone producer prices fell for the first time in nine months in August, with a yearly decline of 0.6%, reversing a previous increase [6][8] - France's industrial production unexpectedly declined by 0.7% in August, with manufacturing output shrinking by 1.6% [7] - The S&P Global UK Composite PMI fell to 50.1 in September, indicating stagnant private sector activity [9] - The S&P Global UK Services PMI decreased to 50.8 in September, marking the weakest pace of expansion since April [10]

Company Strategy - Siemens is considering spinning off a significant portion of its majority stake in Siemens Healthineers, a medical equipment unit listed in Frankfurt [1] - The spinoff structure is relatively untested [1]

Core Insights - Philips is a global leader in health technology, focusing on improving health outcomes through innovative solutions in diagnostic imaging, image-guided therapy, patient monitoring, and health informatics [1] - Citigroup maintains a Neutral rating for Philips, raising its price target to €23 from €22, indicating cautious optimism about the company's future performance [2][6] - Philips showcased new innovations in radiation therapy at the ASTRO 2025 Annual Meeting, introducing the Philips Rembra RT and Philips Areta RT CT platforms aimed at enhancing precision in cancer care [3][6] Stock Performance - The current stock price for Philips (PHG) is $26.82, reflecting a slight increase of approximately 1.00% from the previous day, with fluctuations between $26.78 and $26.97 [4][6] - Over the past year, the stock has experienced a high of $32.91 and a low of $21.48, indicating volatility in its performance [4] - Philips' market capitalization is approximately $24.9 billion, with a trading volume of 790,223 shares on the NYSE, suggesting moderate investor interest [5]

Core Insights - Medtech companies are facing increased tariff uncertainty due to a Section 232 investigation initiated by the Trump administration into medical equipment [1][5] - The investigation began on September 2 and was disclosed by the Department of Commerce [1] - Industry group Advamed is lobbying for exemptions from tariffs, highlighting that 70% of medical equipment used in the U.S. is domestically produced [2] Industry Implications - Advamed's CEO stated that the investigation will demonstrate the strength of U.S. medtech manufacturing and that lower tariffs could lead to increased manufacturing and job growth, benefiting access to lifesaving technologies and reducing costs for hospitals and patients [3] - The investigation encompasses a wide range of medical products, including syringes, IV bags, and complex devices like insulin pumps and imaging machines [4] Potential Outcomes - Major medical device firms, such as Siemens Healthineers and GE Healthcare, have not publicly commented on the investigation, while Philips indicated no immediate operational or financial impact should be assumed [4] - Analysts expect that the investigation may lead to additional tariffs for the medtech industry, potentially following a gradual increase similar to the approach taken with pharmaceuticals [6]

Core Insights - Integra LifeSciences appointed Dr. Raymond Turner as Chief Medical Officer, aiming to enhance clinical development and evidence-based medicine initiatives [2][11][12] Company Overview - Integra LifeSciences, headquartered in Princeton, New Jersey, operates in over 100 countries, focusing on neurosurgery and regenerative surgery [7] - The company’s core products include artificial dura mater, craniofacial repair materials, skin substitutes, and specialized surgical instruments for microsurgery and ENT [7] Recent Developments - In Q4 2024, Integra reported revenues of approximately $442.6 million, with annual revenues around $1.6105 billion, highlighting significant growth in neurosurgery and cerebrospinal fluid management [7] - The company has been actively expanding its product pipeline, including a $275 million acquisition of Johnson & Johnson's Acclarent to enhance its ENT and navigation systems product lines [10] Leadership Impact - Dr. Turner’s extensive clinical and industry experience positions him to bridge the gap between clinical practice and corporate strategy, enhancing the company’s competitive edge [5][9] - His appointment aligns with the industry shift from "engineering-driven" to "clinical-driven" approaches in medical device companies [11] Strategic Focus - The company is implementing a Compliance Master Plan to address production capacity challenges and strengthen its quality and compliance systems [10] - Turner will oversee global clinical trial design and execution, aiming to enhance real-world evidence (RWE) collection to support post-market product value [13]

Core Insights - Integra LifeSciences Holdings Corporation has appointed Dr. Raymond Turner as the new corporate vice president and chief medical officer [1] - Dr. Turner brings over 20 years of experience in clinical operations from leading global MedTech companies and will oversee worldwide medical affairs and clinical development at Integra [2][3] - The appointment is expected to enhance Integra's focus on building robust clinical evidence and improving patient care [3][4] Company Overview - Integra LifeSciences is dedicated to restoring patients' lives through innovative treatment pathways and high-quality medical technology [6] - The company aims to set new standards in surgical, neurologic, and regenerative care [6] Dr. Raymond Turner's Background - Dr. Turner has held senior leadership roles at Siemens Healthineers and Cerenovus, and has extensive experience in neurosurgery [3][5] - He has authored over 150 peer-reviewed publications and participated in more than 70 pre-clinical and clinical research studies [5]